Hepion Pharmaceuticals, Inc.
Hepion Pharmaceuticals (HEPA) received FDA feedback supporting its 505(b)(2) path and Phase 2 design for GV104 in treating gambling disorder. The company plans to file an IND in 2027, according to the company.
Hepion Pharmaceuticals (OTCQB:HEPA) completed its acquisition of Gravitas Life Sciences, gaining two clinical-stage programs, GV104 and GV023, targeting opioid prophylaxis and inflammation. The company also appointed new leadership and outlined 2027 priorities, including regulatory guidance for GV023 and diagnostic validation. Hepion aims to advance its portfolio in liver, immune, and inflammatory diseases.
Hepion Pharmaceuticals acquired Gravitas Life Sciences for $2M in cash and 25M shares, capped at 19.99%. It also paid $1.125M to Canton Strategic Holdings to assume remaining note obligations. The deals aim to expand Hepion's immunology and inflammation pipeline.
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning CTRVP (Hepion Pharmaceuticals, Inc.). Coverage has skewed bullish: 5 bullish, 0 neutral, and 0 bearish.
Recent CTRVP coverage spans mergers & acquisitions, insider activity and corporate actions.
In the last 30 days, CTRVP insiders filed 1 SEC Form 4 transaction — 1 purchase ($10K) and no sales. The most active reporter was Fisher Danina with 1 filing.
Hepion Pharmaceuticals (HEPA) received FDA feedback supporting its 505(b)(2) path and Phase 2 design for GV104 in treating gambling disorder. The company plans to file an IND in 2027, according to the company.
Hepion Pharmaceuticals (OTCQB:HEPA) completed its acquisition of Gravitas Life Sciences, gaining two clinical-stage programs, GV104 and GV023, targeting opioid prophylaxis and inflammation. The company also appointed new leadership and outlined 2027 priorities, including regulatory guidance for GV023 and diagnostic validation. Hepion aims to advance its portfolio in liver, immune, and inflammatory diseases.
Hepion Pharmaceuticals acquired Gravitas Life Sciences for $2M in cash and 25M shares, capped at 19.99%. It also paid $1.125M to Canton Strategic Holdings to assume remaining note obligations. The deals aim to expand Hepion's immunology and inflammation pipeline.
The deal expands Hepion's pipeline and may be viewed positively, but dilution from stock issuance could temper upside.
Minor insider purchase signals modest confidence but size is too small to move the market.
AlphAI scores every news story that mentions CTRVP with an AI model for sentiment and relevance, and aggregates insider trades from Hepion Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Hepion Pharmaceuticals (HEPA) received FDA feedback supporting its 505(b)(2) path and Phase 2 design for GV104 in treating gambling disorder. The company plans to file an IND in 2027, according to the company.
1 min readHepion Pharmaceuticals (OTCQB:HEPA) completed its acquisition of Gravitas Life Sciences, gaining two clinical-stage programs, GV104 and GV023, targeting opioid prophylaxis and inflammation. The company also appointed new leadership and outlined 2027 priorities, including regulatory guidance for GV023 and diagnostic validation. Hepion aims to advance its portfolio in liver, immune, and inflammatory diseases.
2 min readHepion Pharmaceuticals acquired Gravitas Life Sciences for $2M in cash and 25M shares, capped at 19.99%. It also paid $1.125M to Canton Strategic Holdings to assume remaining note obligations. The deals aim to expand Hepion's immunology and inflammation pipeline.
1 min readHepion Pharmaceuticals, Inc. (CTRVP) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Item 1.01 Entry into a Material Definitive Agreement. On October 6, 2026, Hepion Pharmaceuticals, Inc. (the “Company”) entered into a Membership Interest Purchase Agreement (the “Purchase Agreement”) with Gravitas Life Sciences, LLC, a Delaware limited liability company (“GLS”),
2 min readFisher Danina purchased 200,000 shares of Hepion Pharmaceuticals, Inc. (CTRVP) at $0.05 on 2026-09-29.
1 min readHepion Pharmaceuticals, Inc. (CTRVP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 3, 2026, Hepion Pharmaceuticals, Inc. (the “Company”) entered into a convertible note purchase agreement (the “Agreement”) with Gravitas Capital LP (“Gravitas”) pursuant to which the Company issued a $500,000 secu
1 min readHepion Pharmaceuticals, Inc. (CTRVP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 25, 2026, Hepion Pharmaceuticals, Inc. (the “Company”) entered into securities purchase agreements (the “Agreements”) with certain accredited investors (the “Investors”) pursuant to which the Company agreed to sell a
1 min readHepion Pharmaceuticals, Inc. (CTRVP) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers: Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers . On August 19, 2026, the Board of Directors of Hepion Pharmaceuticals, Inc. (the “Company”) approved the appointment of Jam
1 min readStetz Gary S. II purchased 500,000 shares of Hepion Pharmaceuticals, Inc. (CTRVP) at $0.05 on 2026-08-03.
1 min readStetz Gary S. (Interim CEO) purchased 2,000,000 shares of Hepion Pharmaceuticals, Inc. (CTRVP) at $0.05 ($0.10M total) on 2026-08-03.
1 min read
